Patents Examined by Sandra E Dillahunt
  • Patent number: 11384143
    Abstract: The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: July 12, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Madhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
  • Patent number: 11304993
    Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 19, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventors: Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
  • Patent number: 11306140
    Abstract: Methods and compositions for reducing the activity or number of memory Th17 cells in ocular tissue, and for treatment and/or prevention of ocular immunoinflammatory diseases are described.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 19, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Sunil Chauhan, Yihe Chen
  • Patent number: 11291709
    Abstract: Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: April 5, 2022
    Assignee: RANI THERAPEUTICS, LLC
    Inventors: Mercedes Morales, Mir Imran, Radhika Korupolu, Mir Hashim
  • Patent number: 11278593
    Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: March 22, 2022
    Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
    Inventors: Matthew Campbell, Peter Humphries, Marian Humphries, Anna-Sophia Kiang, Sarah Doyle, Luke O'Neill
  • Patent number: 11278629
    Abstract: Methods for identifying and treating patients having cancer who are likely to respond to treatment with an anti-CD37 immunoconjugate (e.g., IMGN529) are provided.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 22, 2022
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Francesco Bertoni, Angela Romanelli, Callum Sloss
  • Patent number: 11261225
    Abstract: Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: March 1, 2022
    Assignee: INSTITUTE FOR CANCER RESEARCH
    Inventors: Roland L. Dunbrack, Jared Adolf-Bryfogle, Gregory P. Adams, Matthew K. Robinson
  • Patent number: 11260027
    Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: March 1, 2022
    Assignee: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT
    Inventors: Satish Nadig, Carl Atkinson, Ann-Marie Broome, Suraj K. Dixit
  • Patent number: 11262363
    Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: March 1, 2022
    Assignee: Astute Medical, Inc.
    Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
  • Patent number: 11241497
    Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 8, 2022
    Assignee: The Schepens Eye Research Institute, Inc.
    Inventors: Reza Dana, Sunil Chauhan
  • Patent number: 11242564
    Abstract: The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: February 8, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jerome Galon, Franck Pages, Bernard Mlecnik, Gabriela Bindea
  • Patent number: 11243202
    Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: February 8, 2022
    Assignees: ASTUTE MEDICAL, INC., UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER
    Inventors: Paul McPherson, John A. Kellum, Jr., Alexander Zarbock
  • Patent number: 11243217
    Abstract: The present invention provides methods and compositions for identifying patients at risk of kidney injury. A risk score, which is a composite of a urinary concentration of IGFBP7 (insulin-like growth factor-binding protein 7) and a urinary concentration of TIMP-2 (tissue inhibitor of metalloproteinase 2), is determined obtained from the patient, and is used to manage patient treatment.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: February 8, 2022
    Assignees: Astute Medical, Inc., University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Paul McPherson, James Patrick Kampf, John A. Kellum
  • Patent number: 11242395
    Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 8, 2022
    Assignee: Adagene Inc.
    Inventors: Peter Peizhi Luo, Fangyong Du, Yan Li, Guizhong Liu, Jun Chen, Xiaohong She, Peter Cheung
  • Patent number: 11236176
    Abstract: Compositions and methods of using SerpinF2-binding molecules for preventing and/or reducing organ damage, functional disability or mortality in a patient at risk due to the activity of SerpinF2 and/or plasminogen activators on tissue injury. Also provided are compositions and methods of using SerpinF2-binding molecules for inhibiting hemorrhage, edema, and apoptosis. Methods for the preparation of medicaments for such methods of treatment and prevention are provided.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: February 1, 2022
    Assignee: Translational Sciences Inc.
    Inventor: Guy L. Reed
  • Patent number: 11236169
    Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 1, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Nelson Ruiz-Opazo, Victoria L. M. Herrera, Francis Joseph Carr
  • Patent number: 11229683
    Abstract: Methods and compositions comprising hematopoietic growth factor proteins and/or protein analogs thereof and/or combinations thereof and angiotensin converting enzyme inhibitors to treat the acute and long term adverse effects of radiation exposure in subjects who have been or will be exposed to radiation are disclosed.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: January 25, 2022
    Assignees: Bolder Biotechnology, Inc., Indiana University Research and Technology Corporation, The Medical College of Wisconsin, Inc.
    Inventors: George N. Cox, Christie M. Orschell, Meetha Manek Medhora, Brian Fish
  • Patent number: 11229641
    Abstract: Compounds and pharmaceutical compositions thereof for inducing apoptosis in a cell expressing Bcl-2 and IP3R and their use in a method for treating neoplastic disorders in a subject.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: January 25, 2022
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Clark Distelhorst
  • Patent number: 11229645
    Abstract: The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: January 25, 2022
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Rosa Barreira Da Silva, Matthew Albert
  • Patent number: 11224685
    Abstract: A bioreactor is provided which contains cells capable of producing cytokine inhibitors in response to cytokines, in a manner regulated by the local or systemic milieu of an individual patient and predicted by mechanistic computational simulations. The bioreactor transfers the cytokine inhibitors to a patient in need of control of the inflammation process as part of a disease or condition in the patient, such as sepsis, trauma, traumatic brain injury, or wound healing. Related methods also are provided.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: January 18, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Yoram Vodovotz, Alexey Solovyev, David Okonkwo, Maxim Mikheev, Qi Mi, Jorg Gerlach, Gregory M. Constantine